Prolonged Survival in Patients with Lung Cancer with Diabetes Mellitus

Hatlen, Peter; Grønberg, Bjørn Henning; Langhammer, Arnulf; Carlsen, Sven Magnus; Amundsen, Tore

doi:10.1097/jto.0b013e31822a75be

Cited by 68 publications

(47 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, this mechanism has not yet been confirmed. Notably, Hatlen et al (5) reported that patients with DM have a reduced propensity for metastatic disease and that this may partially account for the improved survival of lung cancer patients with DM. Although this previous study had a large sample size, only 4.5% of the patients with lung cancer had DM, which is lower than the prevalence of DM in middle-aged and elderly patients in developed countries (16,17).…”

Section: Discussionmentioning

confidence: 99%

“…Although this previous study had a large sample size, only 4.5% of the patients with lung cancer had DM, which is lower than the prevalence of DM in middle-aged and elderly patients in developed countries (16,17). In the study by Hatlen et al (5), diabetic patients were defined as those who disclosed their diabetic condition in a questionnaire and were taking medication for diabetes. In addition, the majority of patients in this previous study had very short survival, regardless of whether they had DM (42 patients; median survival, 8 months) or not (989 patients; median survival, 5 months) (5).…”

Section: Discussionmentioning

confidence: 99%

“…However, the influence of DM on the prognosis of patients with lung cancer remains to be established. In patients with lung cancer, two previous studies have demonstrated that patients with DM survived longer than those without (4,5). In one of these studies (4), the conclusion was based on a small number of patients with unclear diagnostic criteria for DM and inappropriate statistical analyses.…”

Section: Introductionmentioning

confidence: 99%

“…In one of these studies (4), the conclusion was based on a small number of patients with unclear diagnostic criteria for DM and inappropriate statistical analyses. In the other study (5), whilst a larger patient cohort was included, the proportion of patients with lung cancer with DM was low (4.5%) and the definition of DM was ambiguous. In addition, the survival was very short, regardless of whether the patients had DM.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Survival of patients with lung cancer and diabetes mellitus

Kurishima

Watanabe

Ishikawa

et al. 2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Diabetes mellitus (DM) and lung cancer are two highly globally prevalent diseases. The current study aimed to determine the prognostic significance of DM comorbidity in patients with lung cancer. All patients diagnosed at Tsukuba Medical Center Hospital and Mito Medical Center, (University of Tsukuba, Ibaraki, Japan) between April 1999 and March 2012 were followed up to 2015 and were retrospectively analyzed. DM was defined as a fasting plasma glucose (FPG) level ≥126 mg/dl, a non-FPG level ≥200 mg/dl, or a hemoglobin (Hb) A1c level ≥6.5%. Additionally, patients taking medication for diabetes and those with a history of using such medications were also classified as having DM. During the study period, 1,798 patients with lung cancer were diagnosed. Within this cohort, 338 (18.8%) were classed as having lung cancer and DM. In univariate and multivariate analyses, smoking status, poorer performance status, small cell lung cancer pathology, metastatic disease and supportive care were the only unfavorable prognostic factors (all P= 0.001). Additionally, multivariate analysis revealed that existing DM was an unfavorable disease-modifying factor (P= 0.03612). Therefore, DM comorbidity adversely affects lung cancer outcomes. To provide prolonged quality of survival, appropriate pre-evaluation of lung cancer, as well as the patient's medical condition, including DM, is required.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Survival of patients with lung cancer and diabetes mellitus

Kurishima

Watanabe

Ishikawa

et al. 2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…It has also been found that good performance status (PS), disease stage, age and weight loss are strong prognostic factors in this malignancy. Although the prognostic significance of pre-existing DM in patients with lung cancer was evaluated in a number of studies [20][21][22][23][24][25][26][27], their findings were inconsistence. Three studies reported a shorter survival for patients with DM compared to those without DM [20][21][22].…”

Section: Introductionmentioning

confidence: 99%

Prognostic Significance of Diabetes Mellitus in Locally Advanced Non-small Cell Lung Cancer

Imai¹

2017

kmj

View full text Add to dashboard Cite

show abstract

Poor glycemic control might compromise the efficacy of chemotherapy in non‐small cell lung cancer patients with diabetes mellitus

Zeng

Cheng

et al. 2019

Cancer Medicine

View full text Add to dashboard Cite

Background: Previous studies indicated that type 2 diabetes mellitus (T2DM) is related to an increased lung cancer risk, but its role in the prognosis of NSCLC remains conflicting. This study investigated the impact of blood glucose control on the outcomes in NSCLC patients with T2DM treated with platinum-based doublets. Methods: Clinicopathological and survival data from 191 T2DM patients with advanced NSCLC, who received platinum-based chemotherapy, were retrospectively analyzed. Based on the blood glucose conditions during chemotherapy, patients were classified into poor (n = 84) and good control (n = 107) groups. Progression-free survival (PFS) was assessed using the Kaplan-Meier method. Results: The median PFS among patients with good glycemic control [197.0 (95% CI: 136.3-257.7) days] was longer than that among those with poor control [132.0 (95% CI: 112.5-151.5) days] (P = .0003). Further subgroup analysis of lung squamous carcinoma and adenocarcinoma patients showed that the median PFS of the good control group was also significantly longer than that of the poor control group [179.0 (95% CI: 78.4-279.6) days vs 125.0 (95% CI: 110.9-139.1) days, P = .0014;197.0 (95% CI: 124.3-269.7) days vs 154.0 (95% CI: 129.9-178.1) days, P = .0359; respectively]. The incidence rates of side effects were similar among patients with good glycemic control and those with poor glycemic control (all P > .05). Conclusions: Satisfactory glycemic control during platinum-based chemotherapy might provide a survival benefit to T2DM patients with NSCLC. Further studies are warranted to confirm our findings. K E Y W O R D Sglycemic control level, non-small cell lung cancer, platinum-based chemotherapy, progression-free survival, type 2 diabetes mellitus | 903 ZENG Et al.

show abstract

Prolonged Survival in Patients with Lung Cancer with Diabetes Mellitus

Abstract: Patients with lung cancer with diabetes mellitus have an increased survival compared with those without diabetes mellitus.

Cited by 68 publications

References 19 publications

Survival of patients with lung cancer and diabetes mellitus

Survival of patients with lung cancer and diabetes mellitus

Prognostic Significance of Diabetes Mellitus in Locally Advanced Non-small Cell Lung Cancer

Poor glycemic control might compromise the efficacy of chemotherapy in non‐small cell lung cancer patients with diabetes mellitus

Contact Info

Product

Resources

About